Business Description
Burning Rock Biotech Ltd
ISIN : US12233L1070
Share Class Description:
LSE:BNR: ADRDescription
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 49.91 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -4.72 | |||||
| Beneish M-Score | -4.4 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -8.5 | |||||
| 3-Year EBITDA Growth Rate | 5.2 | |||||
| 3-Year EPS without NRI Growth Rate | 5.4 | |||||
| 3-Year FCF Growth Rate | -2.1 | |||||
| 3-Year Book Growth Rate | -33.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 99.98 | |||||
| 9-Day RSI | 96.6 | |||||
| 14-Day RSI | 78.04 | |||||
| 6-1 Month Momentum % | -18.01 | |||||
| 12-1 Month Momentum % | -71.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.36 | |||||
| Quick Ratio | 3.09 | |||||
| Cash Ratio | 2.34 | |||||
| Days Inventory | 211.58 | |||||
| Days Sales Outstanding | 88.04 | |||||
| Days Payable | 59.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.7 | |||||
| Shareholder Yield % | 7.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.6 | |||||
| Operating Margin % | -124.56 | |||||
| Net Margin % | -121.66 | |||||
| FCF Margin % | -47.94 | |||||
| ROE % | -67.69 | |||||
| ROA % | -49.69 | |||||
| ROIC % | -153.67 | |||||
| ROC (Joel Greenblatt) % | -287.99 | |||||
| ROCE % | -65.75 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.11 | |||||
| PB Ratio | 0.77 | |||||
| Price-to-Tangible-Book | 0.77 | |||||
| EV-to-EBIT | 0.02 | |||||
| EV-to-EBITDA | 0.02 | |||||
| EV-to-Revenue | -0.02 | |||||
| EV-to-FCF | 0.05 | |||||
| Price-to-Net-Current-Asset-Value | 0.96 | |||||
| Price-to-Net-Cash | 1.72 | |||||
| Earnings Yield (Greenblatt) % | 5000 | |||||
| FCF Yield % | -43.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Burning Rock Biotech Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 75.544 | ||
| EPS (TTM) ($) | -8.97 | ||
| Beta | 0 | ||
| Volatility % | 49.84 | ||
| 14-Day RSI | 78.04 | ||
| 14-Day ATR ($) | 0.00037 | ||
| 20-Day SMA ($) | 0.84304 | ||
| 12-1 Month Momentum % | -71.97 | ||
| 52-Week Range ($) | 0.7691 - 2.98 | ||
| Shares Outstanding (Mil) | 102.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Burning Rock Biotech Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Burning Rock Biotech Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Burning Rock Biotech Ltd Frequently Asked Questions
What is Burning Rock Biotech Ltd(LSE:BNR)'s stock price today?
The current price of LSE:BNR is $0.85. The 52 week high of LSE:BNR is $2.98 and 52 week low is $0.77.
When is next earnings date of Burning Rock Biotech Ltd(LSE:BNR)?
The next earnings date of Burning Rock Biotech Ltd(LSE:BNR) is 2024-05-30 Est..
Does Burning Rock Biotech Ltd(LSE:BNR) pay dividends? If so, how much?
Burning Rock Biotech Ltd(LSE:BNR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers